Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,955.84 +277.66 (+0.40%) CMC Crypto 200
1,518.33 +29.79 (+2.00%)
GOSS May 2024 3.000 put
| Previous close | 1.5100 |
| Open | 1.5100 |
| Bid | 1.9000 |
| Ask | 3.0000 |
| Strike | 3.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.5100 - 1.5100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireGossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
SAN DIEGO, May 14, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.
Business WireGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awar
Business WireGossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 07, 2024--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
